关注
Lluis Puig
Lluis Puig
Head, Department of Dermatology, Hospital de la Santa Creu i Sant Pau
在 santpau.cat 的电子邮件经过验证
标题
引用次数
引用次数
年份
Secukinumab in plaque psoriasis—results of two phase 3 trials
RG Langley, BE Elewski, M Lebwohl, K Reich, CEM Griffiths, K Papp, ...
New England Journal of Medicine 371 (4), 326-338, 2014
22432014
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
IB McInnes, A Kavanaugh, AB Gottlieb, L Puig, P Rahman, C Ritchlin, ...
The Lancet 382 (9894), 780-789, 2013
9052013
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions
BB Davidovici, N Sattar, PC Jörg, L Puig, P Emery, JN Barker, ...
Journal of Investigative Dermatology 130 (7), 1785-1796, 2010
8822010
Phase 3 studies comparing brodalumab with ustekinumab in psoriasis
M Lebwohl, B Strober, A Menter, K Gordon, J Weglowska, L Puig, K Papp, ...
New England Journal of Medicine 373 (14), 1318-1328, 2015
8462015
Epidemiology of atopic dermatitis in adults: results from an international survey
S Barbarot, S Auziere, A Gadkari, G Girolomoni, L Puig, EL Simpson, ...
Allergy 73 (6), 1284-1293, 2018
7952018
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological …
C Ritchlin, P Rahman, A Kavanaugh, IB McInnes, L Puig, S Li, Y Wang, ...
Annals of the rheumatic diseases 73 (6), 990-999, 2014
7222014
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and …
KB Gordon, B Strober, M Lebwohl, M Augustin, A Blauvelt, Y Poulin, ...
The Lancet 392 (10148), 650-661, 2018
6122018
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
MG Lebwohl, H Bachelez, J Barker, G Girolomoni, A Kavanaugh, ...
Journal of the American Academy of Dermatology 70 (5), 871-881. e30, 2014
5772014
European consensus statement on phenotypes of pustular psoriasis
AA Navarini, AD Burden, F Capon, U Mrowietz, L Puig, S Köks, K Kingo, ...
Journal of the European Academy of Dermatology and Venereology 31 (11), 1792 …, 2017
4422017
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial
RG Langley, TF Tsai, S Flavin, M Song, B Randazzo, Y Wasfi, J Jiang, ...
British Journal of Dermatology 178 (1), 114-123, 2018
3692018
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity
CC Zouboulis, T Tzellos, A Kyrgidis, GBE Jemec, FG Bechara, ...
British Journal of Dermatology 177 (5), 1401-1409, 2017
3582017
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of …
A Kavanaugh, C Ritchlin, P Rahman, L Puig, AB Gottlieb, S Li, Y Wang, ...
Annals of the rheumatic diseases 73 (6), 1000-1006, 2014
3082014
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
JMGR de Morales, L Puig, E Daudén, JD Cañete, JL Pablos, AO Martín, ...
Autoimmunity reviews 19 (1), 102429, 2020
2792020
Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin
MT Fernandez‐Figueras, C Carrato, X Sáenz, L Puig, E Musulen, ...
Journal of the European Academy of Dermatology and Venereology 29 (5), 991-997, 2015
2562015
The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
G Girolomoni, R Strohal, L Puig, H Bachelez, J Barker, WH Boehncke, ...
Journal of the European Academy of Dermatology and Venereology 31 (10), 1616 …, 2017
2552017
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin‐17 inhibitors and their practical management
DM Saunte, U Mrowietz, L Puig, C Zachariae
British Journal of Dermatology 177 (1), 47-62, 2017
2412017
Obesity and psoriasis: body weight and body mass index influence the response to biological treatment
L Puig
Journal of the European Academy of Dermatology and Venereology 25 (9), 1007-1011, 2011
2322011
Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis
AW Armstrong, L Puig, A Joshi, M Skup, D Williams, J Li, KA Betts, ...
JAMA dermatology 156 (3), 258-269, 2020
2282020
Clinical and genetic differences between pustular psoriasis subtypes
S Twelves, A Mostafa, N Dand, E Burri, K Farkas, R Wilson, HL Cooper, ...
Journal of allergy and clinical immunology 143 (3), 1021-1026, 2019
2122019
PASI 90 response: the new standard in therapeutic efficacy for psoriasis
L Puig
Journal of the European Academy of Dermatology and Venereology 29 (4), 645-648, 2015
2062015
系统目前无法执行此操作,请稍后再试。
文章 1–20